Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of protein kinase A activator in preparation of medicament for treating diseases related to reduction of number of platelets

A technique for thrombocytopenia and protein kinase, which is applied in the field of protein kinase A activator to prepare medicines for treating diseases related to the reduction of platelet count, and achieves the effects of broad clinical application prospects, improving PKA activity and protecting platelet apoptosis.

Active Publication Date: 2018-07-31
SUZHOU UNIV
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether PKA has a greater impact on platelet apoptosis induced by storage or pathological stimuli remains unknown.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of protein kinase A activator in preparation of medicament for treating diseases related to reduction of number of platelets
  • Use of protein kinase A activator in preparation of medicament for treating diseases related to reduction of number of platelets
  • Use of protein kinase A activator in preparation of medicament for treating diseases related to reduction of number of platelets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0045] 1. Reagents and materials:

[0046] Anti-GpIIb / IIIa monoclonal antibody SZ21 was provided by Professor Ruan Changgeng, Director of Jiangsu Institute of Hematology, dimethyl sulfoxide (DMSO) and anti-Actin primary antibody were purchased from Sigma, USA, and EDTA-K2 anticoagulant tubes were purchased from BD, USA Company, fluorescein isothiocyanate (Fluorescein Isothiocyanate, FITC)-Annexin V was purchased from Beijing Jiamei Biotechnology Co., Ltd., FITC-goat anti-mouse antibody was purchased from American Bioworld Technology Company, (Horse Radish Peroxidase, HRP)-goat anti-mouse , HRP-goat anti-rabbit, rabbit and mouse IgG, anti-BAX, anti-BAK, anti-Bcl-xL, anti-Bcl-2, anti-Caspase-3, anti-BAD155 phosphorylated antibodies were purchased from Santa Cruz Biotechnology Company, USA, anti-PKA Cα Antibodies were purchased from CST Company in the United States, N-[2-((p-Bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H89), Forsklin, anti-GAPDH, anti-P53 antibody, JC-1,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses use of a protein kinase A activator in preparation of a medicament for treating diseases related to reduction of number of platelets. The method, for the first time, explores the role of protein kinase A in regulation of platelet apoptosis process, and finds that the activity of the protein kinase A in platelets in patients with thrombocytopenia represented by idiopathic thrombocytopenic purpura, bacterial infection and diabetes is decreased. Studies show that protein kinase A regulates the platelet apoptosis by regulating phosphorylation of serine at 155-site of BAD, and by activation of the activity of the protein kinase A, endogenous platelet apoptosis can be inhibited. The protein kinase A activator can inhibit the occurrence of the platelet apoptosis invitro, and also increases the number of circulating platelets in experimental animals. The studies suggest that the PKA activator can be used in the clinical treatment of the thrombocytopenia by inhibiting the platelet apoptosis. The PKA activator has a potential for development of new platelet protection drugs, and is of great scientific research and economic value.

Description

technical field [0001] The invention belongs to the field of platelet-related medicines, and in particular relates to the use of protein kinase A activators in the preparation of medicines for treating diseases related to platelet count reduction. Background technique [0002] Platelets finely regulate blood circulation related thrombus and bleeding balance. At the same time, platelets play an important role in many important pathophysiological processes, such as: immunity, infection, arteriosclerosis, tumor development and metastasis, etc. However, the lifespan of platelets is very short and mysterious, why platelets circulate in the body for only 8-9 days? This problem has plagued mankind for more than half a century. In addition, life-threatening thrombocytopenia often occurs in many high-morbidity diseases, such as diabetes, infection, ITP, and after many pharmacological treatments. The reasons for the shortened platelet lifespan during these pathological processes ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/522A61K31/5575A61K31/7076A61P7/04A61P7/06A61P7/00
CPCA61K31/522A61K31/5575A61K31/7076A61K45/00
Inventor 戴克胜
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products